Celltrion’s biosimilar ‘Remsima’ cruising European market

The world’s first biosimilar antibody developed by Celltrion, Remsima, has exceeded 70% in the European market share.

According to Celltrion, the Remsima’s market share growth rate in the last 1^st quarter’s entire infliximab market was analyzed at 73% which was significantly increased from the 2015 4^th quarter’s growth rate, 37%; moreover, the market share exceeded 30% in the European inflixim...